PharmaDepth

Company profile

JOURNEY MEDICAL CORP

NASDAQ:DERMBiotechnology: Pharmaceutical Preparations

Drug pipeline (7)

AssetStageRevenueTrialsStatus
EMROSIapproved$8.1MQ2 20260—
QBREXZAapproved$5.1MQ2 20260—
AMZEEQapproved$0.9MQ2 20260—
ZILXIapproved$0.9MQ2 20260—
EURAXapproved$0.1MQ2 20260—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (10)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05452785phase1completed2022-05-072022-05-25Journey Medical CorporationA Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
NCT02016885phase2completed2013-11-012014-09-01Journey Medical CorporationA Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
NCT05296629phase3completed2022-03-142023-06-30Journey Medical CorporationA Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
NCT03880266phase2completed2019-02-222019-05-24Journey Medical CorporationA Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
NCT05343455phase3completed2022-03-292023-06-30Journey Medical CorporationA Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

FDA applications (9)

ApplicationApprovedTypeApplicantProducts
NDA 2190152024-11-01NDAJOURNEY MEDICAL CORP
NDA 2136902020-05-28NDAJOURNEY MEDICAL CORP
NDA 2123792019-10-18NDAJOURNEY MEDICAL CORP
NDA 2103612018-06-28NDAJOURNEY MEDICAL CORP
NDA 2019222012-07-11NDAJOURNEY MEDICAL CORP